Free RAPS RAC-US Exam 2023 Practice Materials Collection
RAC-US Exam Info and Free Practice Test All-in-One Exam Guide Aug-2023
NEW QUESTION # 49
Following the introduction of a new regulation, an evaluation of the company's products by the regulatory affairs professional indicates that 60 percent do not comply with the regulation.
What should the regulatory affairs professional do FIRST to meet the new requirement?
- A. Communicate with the relevant internal departments.
- B. Contact the trade association for advice.
- C. Prepare documents for the files.
- D. Request a permanent waiver from the new regulation.
Answer: A
NEW QUESTION # 50
According to WHO, what are the temperature and humidity conditions for a Zone IVb long- term stability study?
- A. 30: C and 75% RH
- B. 25: C and 60% RH
- C. 30 C and 35% RH
- D. 30c C and 65% RH
Answer: A
NEW QUESTION # 51
A regulatory affairs professional has submitted a package for regulatory review.
According to the regulation, the regulatory authority will need to respond within 90 days of submission.
If there is no response after the deadline, what is the BEST approach?
- A. Contact the regulatory authority, ask for clarification about the delay, and demand a decision be made regarding the submission.
- B. Contact the local political representative and ask for intervention with the regulatory authority to obtain a decision regarding the submission.
- C. Contact the regulatory authority, ask for clarification about the delay, and provide answers to any outstanding questions.
- D. Contact the company legal representative in order to begin legal proceedings to enforce the regulatory authority's response time.
Answer: C
NEW QUESTION # 52
Which of the following is the BEST approach for mitigating potential regulatory compliance issues at your company?
- A. Train all new employees on regulatory compliance processes and assign a mentor to them.
- B. Document any failure to follow regulatory compliance processes in employee performance reviews.
- C. Develop documented procedures for regulatory compliance processes and train personnel.
- D. Train employees on all regulatory compliance processes using state-of-the-art systems.
Answer: C
NEW QUESTION # 53
During new drug development, a new impurity in the drug substance is detected at a level of 0.12%. The intended maximum daily dose Is less than 2 g/day, and the drug Is known generally not to be toxic.
What should be done in response to identifying the impurity?
- A. Perform a non-clinical qualification study, wait until the result is available, and then consider performing an identification study.
- B. Perform either an identification study or a non-clinical qualification study.
- C. Perform an identification study, wait until the result is available, and then consider performing a non-clinical qualification study.
- D. Perform both identification and non-clinical qualification studies concurrently.
Answer: C
NEW QUESTION # 54
Which of the following is NOT required to be included in a marketing application?
- A. Administrative forms
- B. Final printed label
- C. Quality, safety, and efficacy Information
- D. Evidence of fee payment
Answer: D
NEW QUESTION # 55
As a member of the product launch review committee, a regulatory affairs professional discovers a major issue with the labeling of a product prior to production. In addition to informing the committee, which is the BEST approach to address the issue?
- A. Delay the start of product production.
- B. Correct the label text.
- C. Abort the product launch.
- D. Inform the regulatory authorities.
Answer: D
NEW QUESTION # 56
A company is developing a new medical device.
During which initial stage is it MOST appropriate (or a regulatory affairs professional to become involved?
- A. Concept development and early technical design
- B. Product release and validation
- C. Concept development and validation
- D. Early technical design and product release
Answer: A
NEW QUESTION # 57
A regulatory authority announces an inspection of a regulatory affairs professional's facility during a holiday season when most of the staff Is not available. What is the MOST practical approach to this dilemma?
- A. Insist that key personnel be available for the inspection.
- B. Negotiate with colleagues and the authority to find a better time.
- C. Arrange for an inspection without all intended personnel.
- D. Inform the authority that the time is not suitable and request a new time
Answer: B
NEW QUESTION # 58
Which of the following is the MOST desirable timing and approach for a regulatory affairs professional who wants to provide feedback on proposed new regulations?
- A. After the enactment of the regulation, through the industry representative
- B. After the enactment of the regulation, through a product-specific meeting
- C. Before the enactment of the regulation, through the industry representative
- D. Before the enactment of the regulation, through formal comments gathering process
Answer: D
NEW QUESTION # 59
According to the ICH guideline on GMP for API, to which of the following is the MOST stringent requirement applied?
- A. Physical processing and packaging
- B. Introduction of the API starting material
- C. Production of Intermediate(s)
- D. Isolation and purification
Answer: A
NEW QUESTION # 60
A company is developing a new medical device using innovative technology. Which of the following is MOST critical in working with regulatory authorities?
- A. Frequent communication
- B. Follow-up meeting after submission
- C. Documented agreement
- D. Early collaboration
Answer: A
NEW QUESTION # 61
A company is developing a new product for the global market. A new international guideline will recommend relevant studies in the pediatric population, and the guideline will be effective before the approval of the company's new product.
What is the BEST advice the regulatory affairs professional can provide to minimize the impact of this guideline on the successful registration of the new product?
- A. The new guideline has no impact on the current registration plan since all relevant registration studies are almost completed.
- B. The company should initiate the required pediatric studies immediately to avoid costly delays to the current registration plan.
- C. The company should consult with relevant regulatory authorities to determine the potential impact on the current registration plan.
- D. The new guideline has no impact on the current registration plan, but the company must be prepared to defend its decision.
Answer: C
NEW QUESTION # 62
A company is currently marketing an implantable orthopedic medical device. The R&D department is planning to change the material used for the implant. The R&D department states that the change does not impact the safety and effectiveness of the product.
What action should the regulatory affairs professional take FIRST?
- A. Write a memo to file since the change does not impact product safety and effectiveness.
- B. Review the content of change and supporting data for the equivalency with the current material.
- C. Prepare regulatory submissions that detail the medical device's change in materials.
- D. No action is needed in this situation.
Answer: B
NEW QUESTION # 63
The manufacturer of an API was changed from Company X to Company Y during the late stage of a new drug development. Despite differences in the manufacturing processes of the companies, both APIs meet the current specifications. Which is the MOST appropriate information to include in the final submission documents?
- A. Information deemed appropriate by the regulatory authority
- B. The process information and the comparative analytical result of APIs from both companies
- C. The process information and analytical result of Company Y API
- D. The process information and analytical result of Company X API
Answer: B
NEW QUESTION # 64
In a distribution contract for high-risk medical devices, which of the following regulatory requirements is the MOST important for the distributor?
- A. Local reimbursement requirements
- B. Written procedure for product traceability
- C. Service operation procedures
- D. Training program for sales people
Answer: D
NEW QUESTION # 65
During face-to-face meetings with the regulatory authority to address submission issues, what is the BEST choice for the number of company representatives who should attend?
- A. As many as government attendees
- B. The minimum number of attendees necessary to address the issues
- C. All senior management from the main office
- D. As many as required by international standards
Answer: B
NEW QUESTION # 66
Which of the following is NOT considered a serious adverse event in a cardiovascular clinical trial?
- A. Subject is hospitalized for the purpose of product administration.
- B. Subject's hospitalization is due to an unscheduled hip operation.
- C. Subject is hospitalized due to complications of the product administration.
- D. Subject's hospitalization is prolonged during the clinical trial.
Answer: A
NEW QUESTION # 67
A materials supplier informs a company that it intends to stop supplying a material critical to the manufacture of the company's products. What action should the company take FIRST?
- A. Complete a gap analysis to identify options.
- B. Review the company's existing Quality Management System
- C. Qualify another supplier and execute a supplier agreement.
- D. Reformulate the products with a replacement material.
Answer: C
NEW QUESTION # 68
During a routine review of promotional materials for a product, a regulatory affairs professional discovers an off-label indication. Which of the following would be the FIRST follow-up action for the regulatory affairs professional to take?
- A. Communicate with the sales department to stop using the promotional materials.
- B. Request that doctors stop using the product for the off-label indication.
- C. Allow doctors to use the product for the off-label indication.
- D. Contact the marketing department to recall the product.
Answer: A
NEW QUESTION # 69
......
Regulatory Affairs Certification (RAC) US is a professional certification program offered by RAPS (Regulatory Affairs Professionals Society). The RAC-US certification is an internationally recognized credential that demonstrates a person's expertise in regulatory affairs. Regulatory Affairs Certification (RAC) US certification program is designed for regulatory affairs professionals who are involved in medical device, pharmaceutical, biotechnology, and other healthcare-related industries.
Pass RAPS RAC-US Actual Free Exam Q&As Updated Dump: https://pass4sures.realvce.com/RAC-US-VCE-file.html